Durability of Stavudine, Lamivudine and Nevirapine Among Advanced HIV-1 Infected Patients With/without Prior Co-administration of Rifampicin: a 144-week Prospective Study

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2008 Oct 15

PMID 18851761

Citations 3

Authors

Weerawat Manosuthi

Preecha Tantanathip

Wisit Prasithisirikul

Sirirat Likanonsakul

Somnuek Sungkanuparph

Affiliations

Soon will be listed here.

Abstract

Background: To date, data on the durability of a regimen of stavudine, lamivudine and nevirapine are very limited, particularly from the resource-limited settings.

Methods: A prospective cohort study was conducted among 140 antiretroviral-naïve patients who were enrolled to initiate d4T, 3TC and NVP between November 2004 and March 2005. The objectives were to determine immunological and virological responses after 144 weeks of antiretroviral therapy. Seventy patients with tuberculosis also received rifampicin during the early period of antiviral treatment (TB group).

Results: Of all, median (IQR) baseline CD4 cell count was 31 (14-79) cells/mm3; median (IQR) baseline HIV-1 RNA was 433,500 (169,000-750,000) copies/mL. The average body weight was 55 kilograms. By intention-to-treat analysis at 144 weeks, the overall percentage of patients who achieved plasma HIV-1 RNA <50 copies/mL was 59.3% (83/140). In subgroup analysis, 61.4% (43/70) patients in TB group and 57.1% (40/70) patients in control group achieved plasma HIV-1 RNA <50 copies/mL (RR = 1.194, 95%CI = 0.608-2.346, P = 0.731). Eight (5.8%) patients discontinued d4T due to neuropathy and/or symptomatic lactic acidosis.

Conclusion: The overall durability and efficacy of antiviral response of d4T, 3TC and NVP are satisfied and they are not different between HIV-1 infected patients with and without co-administration of rifampicin due to tuberculosis. However, stavudine-related adverse effects are concerns.

Trial Registration: ClinicalTrials.gov Identifier NCT00703898.

Citing Articles

The Global Health Impact Index: Promoting Global Health.

Hassoun N PLoS One. 2015; 10(12):e0141374.

PMID: 26657064 PMC: 4676606. DOI: 10.1371/journal.pone.0141374.

The effect of tuberculosis treatment on virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic review.

Soeters H, Napravnik S, Patel M, Eron Jr J, Van Rie A AIDS. 2013; 28(2):245-55.

PMID: 24072197 PMC: 4512169. DOI: 10.1097/01.aids.0000434936.57880.cd.

Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature.

Martins M, Reis A, Sales M, Nobre V, Ribeiro D, Rocha M BMC Pharmacol Toxicol. 2013; 14:27.

PMID: 23641931 PMC: 3653703. DOI: 10.1186/2050-6511-14-27.

References

Renaud-Thery F, Nguimfack B, Vitoria M, Lee E, Graaff P, Samb B . Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS. 2007; 21 Suppl 4:S89-95. DOI: 10.1097/01.aids.0000279711.54922.f0. View

Dean G, Back D, de Ruiter A . Effect of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS. 1999; 13(17):2489-90. DOI: 10.1097/00002030-199912030-00029. View

Ribera E, Pou L, Lopez R, Crespo M, Falco V, Ocana I . Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr. 2001; 28(5):450-3. DOI: 10.1097/00042560-200112150-00007. View

van Oosterhout J, Kumwenda J, Beadsworth M, Mateyu G, Longwe T, Burger D . Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. Antivir Ther. 2007; 12(4):515-21. View

McComsey G, Lonergan J . Mitochondrial dysfunction: patient monitoring and toxicity management. J Acquir Immune Defic Syndr. 2004; 37 Suppl 1:S30-5. DOI: 10.1097/01.qai.0000137004.63376.27. View

Autar R, Wit F, Sankote J, Mahanontharit A, Anekthananon T, Mootsikapun P . Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther. 2006; 10(8):937-43. View

Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer N . Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008; 61(4):914-8. PMC: 3596857. DOI: 10.1093/jac/dkn029. View

Lawn S, Myer L, Bekker L, Wood R . Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006; 20(12):1605-12. DOI: 10.1097/01.aids.0000238406.93249.cd. View

Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W . Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis. 2006; 43(2):253-5. DOI: 10.1086/505210. View

10.

Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D, Stryker R . Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection. AIDS. 2007; 22(2):275-9. DOI: 10.1097/QAD.0b013e3282f21b9d. View

11.

Penzak S, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro R . Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 2007; 8(2):86-91. DOI: 10.1111/j.1468-1293.2007.00432.x. View

12.

. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. U.S. Department of Health and Human Services (DHHS). BETA. 1997; :11-22. View

13.

Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T . Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis. 2006; 44(1):141-4. DOI: 10.1086/510078. View

14.

De Beaudrap P, Etard J, Gueye F, Gueye M, Landman R, Girard P . Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients. AIDS Res Hum Retroviruses. 2008; 24(6):753-60. DOI: 10.1089/aid.2007.0295. View

15.

Vella S, Giuliano M, Dally L, Agresti M, Tomino C, Floridia M . Long-term follow-up of zidovudine therapy in asymptomatic HIV infection: results of a multicenter cohort study. The Italian Zidovudine Evaluation Group. J Acquir Immune Defic Syndr (1988). 1994; 7(1):31-8. View

16.

Cohen K, Van Cutsem G, Boulle A, McIlleron H, Goemaere E, Smith P . Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother. 2007; 61(2):389-93. DOI: 10.1093/jac/dkm484. View

17.

Reliquet V, Allavena C, Francois-Brunet C, Perre P, Bellein V, Garre M . Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study. HIV Med. 2006; 7(7):431-6. DOI: 10.1111/j.1468-1293.2006.00402.x. View

18.

Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S . Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006; 43(1):42-6. DOI: 10.1097/01.qai.0000230521.86964.86. View

19.

Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S . Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med. 2008; 9(5):294-9. DOI: 10.1111/j.1468-1293.2008.00563.x. View

20.

Launay O, Roudiere L, Boukli N, DuPont B, Prevoteau du Clary F, Patey O . Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial. Clin Infect Dis. 2004; 38(8):e66-72. DOI: 10.1086/382677. View